Summit Therapeutics File US Annual Report on Form 20-F
Summit Therapeutics plc
("Summit", or the "Company")
SUMMIT THERAPEUTICS FILES US ANNUAL REPORT ON FORM 20-F
Oxford, UK, 31 March 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, provides notification that on 30 March 2017 the Company filed its US Annual Report on Form 20-F for the year ended 31 January 2017 with the US Securities and Exchange Commission ("SEC").
The Form 20-F is available to download, either from the Investors section of the Company website at www.summitplc.com or from the SEC website at www.sec.gov.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit Therapeutics|
Glyn Edwards / Richard Pye (UK office)
Erik Ostrowski / Michelle Avery (US office)
Tel: +44 (0)1235 443 951
+1 617 225 4455
| Cairn Financial Advisers LLP|
Liam Murray / Tony Rawlinson
Tel: +44 (0)20 7213 0880
| N+1 Singer |
Aubrey Powell / Lauren Kettle
Tel: +44 (0)20 7496 3000
| MacDougall Biomedical Communications|
(US media contact)
Tel: +1 781 235 3060
| Consilium Strategic Communications|
(Financial public relations, UK)
Mary-Jane Elliott / Sue Stuart /
Jessica Hodgson / Lindsey Neville
Tel: +44 (0)20 3709 5700
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Summit Therapeutics plc via Globenewswire